Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(2022) In British Journal of Haematology 196(2). p.437-440
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/50240c2f-9098-4b4e-ae96-7960fd0f70f0
- author
- Fjordén, Karin LU ; Ekberg, Sara ; Kuric, Nevzeta ; Smedby, Karin E. ; Lagerlöf, Ingemar ; Larsen, Thomas S. ; Jørgensen, Judit M. ; de Nully Brown, Peter and Jerkeman, Mats LU
- organization
- publishing date
- 2022-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Haematology
- volume
- 196
- issue
- 2
- pages
- 4 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:34435356
- scopus:85113305805
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.17792
- language
- English
- LU publication?
- yes
- id
- 50240c2f-9098-4b4e-ae96-7960fd0f70f0
- date added to LUP
- 2022-03-01 15:19:52
- date last changed
- 2025-03-22 19:43:33
@article{50240c2f-9098-4b4e-ae96-7960fd0f70f0, author = {{Fjordén, Karin and Ekberg, Sara and Kuric, Nevzeta and Smedby, Karin E. and Lagerlöf, Ingemar and Larsen, Thomas S. and Jørgensen, Judit M. and de Nully Brown, Peter and Jerkeman, Mats}}, issn = {{0007-1048}}, language = {{eng}}, number = {{2}}, pages = {{437--440}}, publisher = {{John Wiley & Sons Inc.}}, series = {{British Journal of Haematology}}, title = {{Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial}}, url = {{http://dx.doi.org/10.1111/bjh.17792}}, doi = {{10.1111/bjh.17792}}, volume = {{196}}, year = {{2022}}, }